cycE/CCNE Cancer Research Results
cycE/CCNE, Cyclin E: Click to Expand ⟱
| Source: |
| Type: |
Cyclin E regulates multiple downstream molecules, such as the retinoblastoma susceptibility gene (RB1) and the transcription factor E2F.
Cyclin E (Cyclin E1 and Cyclin E2) is the key regulator of the late G1 → S-phase transition.
Cyclin E is a prognostic marker in breast cancer, its altered expression increased with the increasing stage and grade of the tumor.
Cyclin E is a regulatory protein that plays a critical role in the cell cycle, particularly in the transition from the G1 phase to the S phase. Its expression levels can significantly influence cancer progression and patient prognosis.
Cyclin E expression is frequently elevated in various cancers and is generally associated with poor prognosis. Its role in promoting cell cycle progression makes it a potential biomarker for tumor aggressiveness and patient outcomes.
|
Nor, Normal Healthy: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
Inflam↓, IL6↓, MCP1/CCL2↓, COX2↓, PGE2↓, MMP2↓, MMP9↓, DNAdam↑, eff↝, Telomerase↓, Bcl-2↓, AMPK↑, ROS↑, MMP↓, ATP↓, p‑mTORC1↓, p‑S6K↓, ERK↓, PI3K↓, PTEN↑, Akt↓, Raf↓, MEK↓, Dose↓, Dose↑, selectivity↑, TumCCA↑, eff↑, EGFR↓, Glycolysis↓, Dose?, p27/CDKN1B↑, CDK2↓, CDK4↓, cycD1/CCND1↓, cycE/CCNE↓, Bax:Bcl2↑, Casp3↑, Casp9↑, VEGFR2/KDR/Flk1↓, ChemoSen↑, eff↑, eff↑, PGE2↓, JAK2↓, STAT3↓, CXCR4↓, CCR7↓, uPA↓, CSCs↓, EMT↓, Diff↓, CD133↓, Nestin↓, n-MYC↓, NOTCH↓, SOX2↓, Hif1a↓, VEGF↓, RadioS↑,
| - |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
BC, |
HS587T |
|
|
|
- |
in-vitro, |
Nor, |
MCF10 |
|
|
|
AntiTum↑, tumCV↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, cycE/CCNE↓, CDK2↓, P21↑, p27/CDKN1B↑, Casp9↑, Casp3↑, ROS↑, mtDam↑, i-Ca+2↑, *ROS↓, *Apoptosis↓, TumCG↓,
Showing Research Papers: 1 to 2 of 2
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↑, 2,
Mitochondria & Bioenergetics(tgid=3) ⓘ
ATP↓, 1, MEK↓, 1, MMP↓, 1, mtDam↑, 1, Raf↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
AMPK↑, 1, Glycolysis↓, 1, p‑S6K↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 1, Bax:Bcl2↑, 1, Bcl-2↓, 1, Casp3↑, 2, Casp9↑, 2, p27/CDKN1B↑, 2, Telomerase↓, 1,
Transcription & Epigenetics(tgid=7) ⓘ
tumCV↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNAdam↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK2↓, 2, CDK4↓, 2, cycD1/CCND1↓, 2, cycE/CCNE↓, 2, P21↑, 1, TumCCA↑, 2,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
CD133↓, 1, CSCs↓, 1, Diff↓, 1, EMT↓, 1, ERK↓, 1, p‑mTORC1↓, 1, n-MYC↓, 1, Nestin↓, 1, NOTCH↓, 1, PI3K↓, 1, PTEN↑, 1, SOX2↓, 1, STAT3↓, 1, TumCG↓, 1,
Migration(tgid=13) ⓘ
i-Ca+2↑, 1, MMP2↓, 1, MMP9↓, 1, uPA↓, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
EGFR↓, 1, Hif1a↓, 1, VEGF↓, 1, VEGFR2/KDR/Flk1↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
CCR7↓, 1, COX2↓, 1, CXCR4↓, 1, IL6↓, 1, Inflam↓, 1, JAK2↓, 1, MCP1/CCL2↓, 1, PGE2↓, 2,
Drug Metabolism & Resistance(tgid=21) ⓘ
ChemoSen↑, 1, Dose?, 1, Dose↓, 1, Dose↑, 1, eff↑, 3, eff↝, 1, RadioS↑, 1, selectivity↑, 2,
Clinical Biomarkers(tgid=22) ⓘ
EGFR↓, 1, IL6↓, 1,
Functional Outcomes(tgid=23) ⓘ
AntiTum↑, 1,
Total Targets: 65
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↓, 1,
Cell Death(tgid=5) ⓘ
Apoptosis↓, 1,
Total Targets: 2
Scientific Paper Hit Count for: cycE/CCNE, Cyclin E
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:49 Cells:% prod#:% Target#:378 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page